Janus Activated Kinase inhibition in Myelofibrosis.
Indian J Cancer
;
2012 Jul-Sept; 49(3): 260-265
Article
Dans Anglais
| IMSEAR
| ID: sea-144583
ABSTRACT
Janus Activated Kinase (JAK) 2 plays an important role in the pathogenesis of myelofibrosis (MF). Ruxolitinib (INCB018424, Jakafi) is a potent dual JAK1 and JAK2 inhibitor. In November 2011, it became approved by the US FDA for the treatment of intermediate or high-risk MF. This review shall outline the role of Ruxolitinib in the current management of MF and its potential future.
Texte intégral:
Disponible
Indice:
IMSEAR (Asie du Sud-Est)
Sujet Principal:
Pyrazoles
/
Humains
/
Janus kinase 1
/
Kinase Janus-2
/
Myélofibrose primitive
langue:
Anglais
Texte intégral:
Indian J Cancer
Année:
2012
Type:
Article
Documents relatifs à ce sujet
MEDLINE
...
LILACS
LIS